{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:51:54Z","timestamp":1791427914178,"version":"4.3.3"},"reference-count":149,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The integration of ICIs has reshaped therapeutic strategies in head and neck squamous cell carcinoma (HNSCC). ICIs are established in recurrent\/metastatic (R\/M) HNSCC and have been extensively evaluated in resectable and locoregionally advanced (LA) disease, without success until the recent KEYNOTE-689 and NIVOPOSTOP studies. These pivotal trials demonstrate that perioperative and adjuvant ICIs can improve clinical outcomes and change clinical practice. Their implementation in resectable HNSCC may raise several unanswered questions, including optimal sequencing with surgery and radiotherapy, patient selection, and management of patients who progress to R\/M disease after (neo)adjuvant therapy. This review summarizes the most recent evidence on ICIs in LA-HNSCC, highlighting both successes and challenges in clinical development, clinical practice implications, unresolved questions, and emerging strategies. We provide an overview of ongoing studies exploring ICI-based approaches and combinations for neoadjuvant adaptive response, surgical strategies including surgical conversion and organ preservation, and radiotherapy optimization. Additionally, we review ongoing clinical trials evaluating ICIs in combination with chemotherapy, antibody\u2014drug conjugates, targeted therapy, radiotherapy\u2014including stereotactic body radiotherapy (SBRT), novel ICIs, and therapeutic cancer vaccines targeting HPV or tumor neoantigens.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag366","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:25:05Z","timestamp":1789651505000},"source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitors in resectable and locoregionally advanced HNSCC: past lessons, present evidence, and future directions"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0004-499X","authenticated-orcid":false,"given":"Kaewta","family":"Jeerapradit","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University , 270 Rama VI Road, Ratchathewi, Bangkok, 10400,","place":["Thailand"]},{"name":"Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 111 Moo 14, Bang Pla, Bang Phli, 10540,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-4247","authenticated-orcid":false,"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital , Seoul, 03080,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6535-6345","authenticated-orcid":false,"given":"Nuttapong","family":"Ngamphaiboon","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University , 270 Rama VI Road, Ratchathewi, Bangkok, 10400,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"2026100722465822400_oyag366-B1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jama.2025.21733","article-title":"Head and neck cancer: a review","volume":"335","author":"Dunn","year":"2026","journal-title":"JAMA"},{"key":"2026100722465822400_oyag366-B2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"key":"2026100722465822400_oyag366-B3","doi-asserted-by":"publisher","first-page":"e2400285","DOI":"10.1200\/go-24-00285","article-title":"Changing landscape of head and neck squamous cell carcinoma and nasopharyngeal carcinoma treatment and survival trends in Thailand: a 13-Year multicenter retrospective study of patients","volume":"11","author":"Ngamphaiboon","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"2026100722465822400_oyag366-B4","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med"},{"key":"2026100722465822400_oyag366-B5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N Engl J Med"},{"key":"2026100722465822400_oyag366-B6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/hed.20279","article-title":"Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)","volume":"27","author":"Bernier","year":"2005","journal-title":"Head Neck"},{"key":"2026100722465822400_oyag366-B7","doi-asserted-by":"publisher","first-page":"e70746","DOI":"10.1002\/cam4.70746","article-title":"Postoperative radiation with or without concurrent chemotherapy for patients with locally advanced head and neck squamous cell carcinoma with multiple intermediate risks: a propensity score-matched study","volume":"14","author":"Leewiboonsilp","year":"2025","journal-title":"Cancer Med"},{"key":"2026100722465822400_oyag366-B8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","article-title":"Meta-analysis of chemotherapy in head and neck cancer (mach-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC group","volume":"156","author":"Lacas","year":"2021","journal-title":"Radiother Oncol"},{"key":"2026100722465822400_oyag366-B9","author":"National Comprehensive Cancer Network"},{"key":"2026100722465822400_oyag366-B10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"2026100722465822400_oyag366-B11","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1200\/JCO.2025.43.16_suppl.6086","article-title":"The use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin based chemoradiation: landmark 3-year survival analysis of a randomized phase III trial (DHANUSH)","volume":"43","author":"Dhar","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B12","doi-asserted-by":"publisher","first-page":"100309","DOI":"10.1016\/j.esmoop.2021.100309","article-title":"Pan-Asian adaptation of the EHNS-ESMO-ESTRO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck","volume":"6","author":"Keam","year":"2021","journal-title":"ESMO Open"},{"key":"2026100722465822400_oyag366-B13","doi-asserted-by":"publisher","first-page":"106520","DOI":"10.1016\/j.oraloncology.2023.106520","article-title":"Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma","volume":"145","author":"Ngamphaiboon","year":"2023","journal-title":"Oral Oncol"},{"key":"2026100722465822400_oyag366-B14","doi-asserted-by":"publisher","first-page":"e7047","DOI":"10.1002\/cam4.7047","article-title":"Early recurrence, time-to-recurrence, and recurrence patterns: assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R\/M-HNSCC) patients treated with first line platinum-based chemotherapy","volume":"13","author":"Pitakpaiboonkul","year":"2024","journal-title":"Cancer Med"},{"key":"2026100722465822400_oyag366-B15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/jco.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100722465822400_oyag366-B17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0140-6736(25)01850-1","article-title":"Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial","volume":"407","author":"Bourhis","year":"2026","journal-title":"Lancet"},{"key":"2026100722465822400_oyag366-B18","doi-asserted-by":"crossref","first-page":"S768","DOI":"10.1016\/j.annonc.2025.08.1951","article-title":"Perioperative camrelizumab plus chemotherapy in locally advanced squamous cell carcinoof thead and neck (CAMORAL): a multicenter, open-label, randomized, phase II Study","volume":"36","author":"He","year":"2025","journal-title":"Ann Oncol"},{"key":"2026100722465822400_oyag366-B19","doi-asserted-by":"publisher","first-page":"e18083","DOI":"10.1200\/JCO.2025.43.16_suppl.e18083","article-title":"A phase II exploratory study (NCT06208826) on maintenance immunotherapy in patients with resectable locally advanced head and neck cancer who achieved MPR after neoadjuvant immunotherapy combined with chemotherapy","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B20","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1200\/JCO.2023.41.16_suppl.6068","article-title":"Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal\/hypopharyngeal carcinoma: preliminary results of INSIGHT study","volume":"41","author":"Ou","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B21","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1200\/JCO.2025.43.16_suppl.6084","article-title":"Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma","volume":"43","author":"Bell","year":"2025","journal-title":"Journal of Clinical Oncology"},{"key":"2026100722465822400_oyag366-B22","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2025.43.16_suppl.6043","article-title":"Neoadjuvant immunotherapy in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma: a randomized, open label, phase II clinical trial","volume":"43","author":"Liu","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B23","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1200\/JCO.2025.43.16_suppl.6018","article-title":"Neoadjuvant PD-1 inhibitor combined with nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): a randomized, controlled, open label, phase II clinical trial","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B24","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1200\/JCO.2023.41.16_suppl.6069","article-title":"A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck","volume":"41","author":"Wu","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B25","doi-asserted-by":"publisher","first-page":"105505","DOI":"10.1016\/j.esmoop.2025.105505","article-title":"Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial","volume":"10","author":"Gui","year":"2025","journal-title":"ESMO Open"},{"key":"2026100722465822400_oyag366-B26","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1038\/s41467-025-59865-1","article-title":"Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"key":"2026100722465822400_oyag366-B27","doi-asserted-by":"publisher","first-page":"6583","DOI":"10.1200\/JCO.2020.38.15_suppl.6583","article-title":"Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer","volume":"38","author":"Zinner","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B28","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1001\/jama.2025.1483","article-title":"Atezolizumab in High-Risk locally advanced squamous cell carcinoma of the head and neck: a randomized clinical trial","volume":"333","author":"Haddad","year":"2025","journal-title":"JAMA"},{"key":"2026100722465822400_oyag366-B29","article-title":"Postoperative adjuvant radiochemotherapy with cisplatin (aRCH) vs. aRCH plus pembrolizumab in locally advanced head and neck squamous cell carcinoma (HNSCC): first data of the ADRISK trial","author":"Dietz","year":"2018"},{"key":"2026100722465822400_oyag366-B30","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1200\/JCO.2024.42.16_suppl.6099","article-title":"Survival outcomes of concurrent radiotherapy and toripalimab versus radiotherapy alone for elderly patients with postoperative head and neck squamous cell carcinoma unfit for cisplatin","volume":"42","author":"Dou","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B31","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.1200\/JCO.2023.41.16_suppl.6014","article-title":"co\u2009+\u2009oropharynx cancer","volume":"41","author":"Skinner","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B32","author":"Administration USFD"},{"key":"2026100722465822400_oyag366-B33","author":"Agency"},{"key":"2026100722465822400_oyag366-B34","doi-asserted-by":"publisher","first-page":"S1957","DOI":"10.1016\/j.annonc.2025.10.1103","article-title":"Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) for resectable locally advanced head and neck cancer (LA HNSCC) in the Asian subgroup of the phase III KEYNOTE-689 trial","volume":"36","author":"Tahara","year":"2025","journal-title":"Ann Oncol"},{"key":"2026100722465822400_oyag366-B35","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat Cancer"},{"key":"2026100722465822400_oyag366-B36","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/s41591-023-02710-z","article-title":"Mounting evidence for perioperative immunotherapy","volume":"29","author":"O\u2019Leary","year":"2023","journal-title":"Nat Med"},{"key":"2026100722465822400_oyag366-B37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1158\/1078-0432.Ccr-19-2209","article-title":"Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen\u2013specific T cells","volume":"26","author":"Friedman","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026100722465822400_oyag366-B38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41571-024-00969-w","article-title":"T cell dynamics with neoadjuvant immunotherapy in head and neck cancer","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2026100722465822400_oyag366-B39","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"key":"2026100722465822400_oyag366-B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_349411","article-title":"Neoadjuvant immunotherapy: leveraging the immune system to treat early-stage disease","volume":"42","author":"Mittendorf","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026100722465822400_oyag366-B41","doi-asserted-by":"publisher","first-page":"e010833","DOI":"10.1136\/jitc-2024-010833","article-title":"Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care","volume":"13","author":"Topalian","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026100722465822400_oyag366-B42","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41467-024-46444-z","article-title":"Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"2026100722465822400_oyag366-B43","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1200\/JCO.2024.42.16_suppl.6073","article-title":"Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): an open-label, single-arm, phase 2 study","volume":"42","author":"Wei","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B44","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1016\/S1470-2045(24)00656-9","article-title":"Proceedings of the national cancer institute workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation","volume":"26","author":"Morris","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026100722465822400_oyag366-B45","doi-asserted-by":"publisher","first-page":"102361","DOI":"10.1016\/j.ctrv.2022.102361","article-title":"Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers","volume":"105","author":"Wong","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2026100722465822400_oyag366-B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_351336","article-title":"Introducing checkpoint inhibitors into the curative setting of head and neck cancers: lessons learned, future considerations","volume":"42","author":"Nenclares","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026100722465822400_oyag366-B47","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1200\/JCO.2025.43.16_suppl.6013","article-title":"Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC)","volume":"43","author":"Tao","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B48","article-title":"Results from CompARE phase III RCT: neoadjuvant durvalumab plus chemoradiotherapy followed by adjuvant durvalumab vs chemoradiotherapy alone in intermediate- and high-risk oropharyngeal cancer","author":"Mehanna","year":"2025"},{"key":"2026100722465822400_oyag366-B49","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026100722465822400_oyag366-B50","doi-asserted-by":"publisher","first-page":"S616","DOI":"10.1016\/j.annonc.2024.08.915","article-title":"854MO avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): final analysis of randomized phase III GORTEC 2017-01 REACH trial","volume":"35","author":"Tao","year":"2024","journal-title":"Ann Oncol"},{"key":"2026100722465822400_oyag366-B51","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.014","article-title":"Interim futility results of NRG-HN005, a randomized, phase II\/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients","volume":"120","author":"Yom","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100722465822400_oyag366-B52","doi-asserted-by":"publisher","first-page":"e003747","DOI":"10.1136\/jitc-2021-003747","article-title":"Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer","volume":"10","author":"Hecht","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026100722465822400_oyag366-B53","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1200\/jco-24-01580","article-title":"Randomized phase II study of concurrent versus sequential pembrolizumab in combination with chemoradiation in locally advanced head and neck cancer","volume":"43","author":"Zandberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B54","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jamaoncol.2024.1530","article-title":"Neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer: OPTIMA II phase 2 open-label nonrandomized clinical trial","volume":"10","author":"Rosenberg","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026100722465822400_oyag366-B55","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1001\/jamaoncol.2025.0081","article-title":"Neoadjuvant nivolumab plus chemotherapy followed by response-stratified chemoradiation therapy in HPV-negative head and neck cancer: the DEPEND phase 2 nonrandomized clinical trial","volume":"11","author":"Rosenberg","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026100722465822400_oyag366-B56","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1200\/JCO.2022.40.16_suppl.6060","article-title":"Camrelizumab plus apatinib as induction therapy for locally advanced head and neck squamous cell carcinoma (IMplus): a single-arm phase II study","volume":"40","author":"Ye","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B57","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S1470-2045(24)00507-2","article-title":"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2\/3 trial","volume":"25","author":"Mell","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026100722465822400_oyag366-B58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","article-title":"Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial","volume":"34","author":"Tao","year":"2023","journal-title":"Ann Oncol"},{"key":"2026100722465822400_oyag366-B59","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1158\/1078-0432.Ccr-20-0230","article-title":"Concurrent definitive immunoradiotherapy for patients with stage III-IV head and neck cancer and cisplatin contraindication","volume":"26","author":"Weiss","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026100722465822400_oyag366-B60","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"2026100722465822400_oyag366-B61","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1200\/jco-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non\u2013small cell lung cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B62","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.1038\/s41467-025-61780-4","article-title":"The tumor-sentinel lymph node immuno-migratome reveals CCR7+ dendritic cells drive response to sequenced immunoradiotherapy","volume":"16","author":"Saddawi-Konefka","year":"2025","journal-title":"Nat Commun"},{"key":"2026100722465822400_oyag366-B63","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/1078-0432.Ccr-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026100722465822400_oyag366-B64","author":"Agency"},{"key":"2026100722465822400_oyag366-B65","author":"Lee"},{"key":"2026100722465822400_oyag366-B66","doi-asserted-by":"publisher","first-page":"115055","DOI":"10.1016\/j.ejca.2024.115055","article-title":"Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy","volume":"212","author":"Woodford","year":"2024","journal-title":"Eur J Cancer (1965)"},{"key":"2026100722465822400_oyag366-B67","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026100722465822400_oyag366-B68","doi-asserted-by":"crossref","first-page":"TPS3110","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3110","article-title":"A phase 3, prospective, multicenter, randomized open-label trial to compare the efficacy and safety of tislelizumab (BGB-A317, Anti\u2013PD-1 antibody) combined with chemotherapy followed by surgery versus up-front surgery as treatment for resectable head and neck squamous cell carcinoma","volume":"36","author":"Qin","year":"2018","journal-title":"J Clin Oncol."},{"key":"2026100722465822400_oyag366-B69","year":"2025"},{"key":"2026100722465822400_oyag366-B70","year":"2025"},{"key":"2026100722465822400_oyag366-B71","year":"2025"},{"key":"2026100722465822400_oyag366-B72","year":"2025"},{"key":"2026100722465822400_oyag366-B73","year":"2025"},{"key":"2026100722465822400_oyag366-B74","year":"2025"},{"key":"2026100722465822400_oyag366-B75","year":"2025"},{"key":"2026100722465822400_oyag366-B76","year":"2025"},{"key":"2026100722465822400_oyag366-B77","year":"2025"},{"key":"2026100722465822400_oyag366-B78","year":"2025"},{"key":"2026100722465822400_oyag366-B79","year":"2025"},{"key":"2026100722465822400_oyag366-B80","year":"2025"},{"key":"2026100722465822400_oyag366-B81","year":"2025"},{"key":"2026100722465822400_oyag366-B82","year":"2025"},{"key":"2026100722465822400_oyag366-B83","year":"2025"},{"key":"2026100722465822400_oyag366-B84","year":"2025"},{"key":"2026100722465822400_oyag366-B85","year":"2025"},{"key":"2026100722465822400_oyag366-B86","year":"2025"},{"key":"2026100722465822400_oyag366-B87","year":"2025"},{"key":"2026100722465822400_oyag366-B88","year":"2025"},{"key":"2026100722465822400_oyag366-B89","year":"2025"},{"key":"2026100722465822400_oyag366-B90","year":"2025"},{"key":"2026100722465822400_oyag366-B91","year":"2025"},{"key":"2026100722465822400_oyag366-B92","year":"2025"},{"key":"2026100722465822400_oyag366-B93","year":"2025"},{"key":"2026100722465822400_oyag366-B94","year":"2025"},{"key":"2026100722465822400_oyag366-B95","year":"2025"},{"key":"2026100722465822400_oyag366-B96","year":"2025"},{"key":"2026100722465822400_oyag366-B97","year":"2025"},{"key":"2026100722465822400_oyag366-B98","year":"2025"},{"key":"2026100722465822400_oyag366-B99","year":"2025"},{"key":"2026100722465822400_oyag366-B100","year":"2025"},{"key":"2026100722465822400_oyag366-B101","year":"2025"},{"key":"2026100722465822400_oyag366-B102","year":"2025"},{"key":"2026100722465822400_oyag366-B103","doi-asserted-by":"publisher","first-page":"S655","DOI":"10.1016\/j.annonc.2024.08.2145","article-title":"945tip JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)","volume":"35","author":"Machiels","year":"2024","journal-title":"Annals of Oncology"},{"key":"2026100722465822400_oyag366-B104","year":"2025"},{"key":"2026100722465822400_oyag366-B105","year":"2025"},{"key":"2026100722465822400_oyag366-B106"},{"key":"2026100722465822400_oyag366-B107","year":"2025"},{"key":"2026100722465822400_oyag366-B108","year":"2025"},{"key":"2026100722465822400_oyag366-B109","year":"2025"},{"key":"2026100722465822400_oyag366-B110","year":"2025"},{"key":"2026100722465822400_oyag366-B111","year":"2025"},{"key":"2026100722465822400_oyag366-B112","year":"2025"},{"key":"2026100722465822400_oyag366-B113","year":"2025"},{"key":"2026100722465822400_oyag366-B114","year":"2025"},{"key":"2026100722465822400_oyag366-B115","year":"2025"},{"key":"2026100722465822400_oyag366-B116","year":"2025"},{"key":"2026100722465822400_oyag366-B117","year":"2025"},{"key":"2026100722465822400_oyag366-B118","year":"2025"},{"key":"2026100722465822400_oyag366-B119"},{"key":"2026100722465822400_oyag366-B120","year":"2025"},{"key":"2026100722465822400_oyag366-B121","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1016\/s1470-2045(25)00020-8","article-title":"International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer","volume":"26","author":"Ferrari","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026100722465822400_oyag366-B122","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1200\/JCO.2025.43.16_suppl.6016","article-title":"Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts)","volume":"43","author":"Tourneau","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B123","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1200\/JCO.2023.41.16_suppl.6075","article-title":"Neoadjuvant pembrolizumab, GX-188E, and GX-I7 in patients with human papillomavirus-16- and\/or 18-positive head and neck squamous cell carcinoma: Single-arm, phase 2 trial with single cell transcriptomic analysis and artificial intelligence-powered spatial analysis","volume":"41","author":"Kim","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B124","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/1078-0432.Ccr-13-2617","article-title":"Phase I dendritic cell p53 peptide vaccine for head and neck cancer","volume":"20","author":"Schuler","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026100722465822400_oyag366-B125","year":"2025"},{"key":"2026100722465822400_oyag366-B126","year":"2025"},{"key":"2026100722465822400_oyag366-B127","year":"2025"},{"key":"2026100722465822400_oyag366-B128","doi-asserted-by":"publisher","first-page":"TPS6117","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS6117","article-title":"Phase II trial of neoadjuvant chemotherapy (NAC) docetaxel-cisplatin alone (DC) or with anti-human papillomavirus (HPV) gene therapy PRGN-2009 (DCP) followed by surgery in patients (pts) with newly diagnosed HPV-Associated oropharyngeal cancer (HPV-OPC)","volume":"43","author":"Floudas","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B129","doi-asserted-by":"publisher","first-page":"TPS6115","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS6115","article-title":"Randomized phase I\/II trial of TheraT vectors expressing HPV16 specific antigens with neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) or risk\/response stratified chemoradiotherapy (CRT) for locoregional HPV16+ oropharyngeal cancer (OPC)","volume":"41","author":"Rosenberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026100722465822400_oyag366-B130","year":"2025"},{"key":"2026100722465822400_oyag366-B131","year":"2025"},{"key":"2026100722465822400_oyag366-B132","year":"2025"},{"key":"2026100722465822400_oyag366-B133","year":"2025"},{"key":"2026100722465822400_oyag366-B134","year":"2025"},{"key":"2026100722465822400_oyag366-B135","doi-asserted-by":"publisher","first-page":"103070","DOI":"10.1016\/j.ctrv.2025.103070","article-title":"Circulating tumour DNA in head and neck squamous-cell carcinomas: a literature review","volume":"142","author":"Ventelou","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"2026100722465822400_oyag366-B136","doi-asserted-by":"publisher","first-page":"107760","DOI":"10.1016\/j.oraloncology.2025.107760","article-title":"Circulating tumor DNA in non-viral head and neck squamous cell carcinoma: a systematic review and meta-analysis","volume":"170","author":"Helou","year":"2025","journal-title":"Oral Oncol"},{"key":"2026100722465822400_oyag366-B137","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamaoto.2025.0903","article-title":"ctDNA and recurrence risk for adjuvant de-escalation in HPV-positive oropharyngeal carcinoma: a secondary analysis of the DART phase 3 randomized clinical trial","volume":"151","author":"Routman","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2026100722465822400_oyag366-B138","doi-asserted-by":"publisher","first-page":"104534","DOI":"10.1016\/j.esmoop.2025.104534","article-title":"Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN)","volume":"10","author":"Honor\u00e9","year":"2025","journal-title":"ESMO Open"},{"key":"2026100722465822400_oyag366-B139","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41698-026-01309-0","article-title":"Personalized ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients","volume":"10","author":"Flach","year":"2026","journal-title":"NPJ Precis Oncol"},{"key":"2026100722465822400_oyag366-B140","year":"2026"},{"key":"2026100722465822400_oyag366-B141","year":"2026"},{"key":"2026100722465822400_oyag366-B142","year":"2026"},{"key":"2026100722465822400_oyag366-B143","year":"2026"},{"key":"2026100722465822400_oyag366-B144","year":"2026"},{"key":"2026100722465822400_oyag366-B145","year":"2026"},{"key":"2026100722465822400_oyag366-B146","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41698-024-00759-8","article-title":"Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy","volume":"8","author":"Zhang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026100722465822400_oyag366-B147","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1186\/s12967-025-07280-x","article-title":"Spatial profiling of HPV-stratified head and neck squamous cell carcinoma reveals distinct immune niches and microenvironmental architectures","volume":"23","author":"Markovits","year":"2025","journal-title":"J Transl Med"},{"key":"2026100722465822400_oyag366-B148","doi-asserted-by":"publisher","first-page":"107744","DOI":"10.1016\/j.oraloncology.2025.107744","article-title":"Neoadjuvant chemotherapy combined with anti-PD-1 monoclonal antibody in locally advanced resectable oral squamous cell carcinoma: efficacy evaluation and prediction","volume":"170","author":"He","year":"2025","journal-title":"Oral Oncol"},{"key":"2026100722465822400_oyag366-B149","doi-asserted-by":"publisher","first-page":"e2300003","DOI":"10.1200\/po.23.00003","article-title":"Six-microRNA prognostic signature in patients with locally advanced head and neck squamous cell carcinoma","volume":"7","author":"Worakitchanon","year":"2023","journal-title":"JCO Precis Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag366\/71189023\/oyag366.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag366\/71189023\/oyag366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag366\/71189023\/oyag366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:47:04Z","timestamp":1791427624000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag366\/8812275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":149,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag366","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,17]]},"article-number":"oyag366"}}